Eagle Global Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $219K | Hold |
1,395
| – | – | 0.01% | 262 |
|
|
2026
Q1 | $213K | Buy |
+1,395
| New | +$214K | 0.01% | 267 |
|
|
2023
Q2 | – | Sell |
-3,340
| Closed | -$307K | – | 229 |
|
|
2023
Q1 | $307K | Sell |
3,340
-24,413
| -88% | -$2.13M | 0.02% | 189 |
|
|
2022
Q4 | $2.52M | Sell |
27,753
-477
| -2% | -$40.2K | 0.17% | 94 |
|
|
2022
Q3 | $2.15M | Sell |
28,230
-858
| -3% | -$71.1K | 0.16% | 109 |
|
|
2022
Q2 | $2.46M | Sell |
29,088
-1,215
| -4% | -$107K | 0.18% | 104 |
|
|
2022
Q1 | $2.66M | Buy |
30,303
+142
| +0.5% | +$12.3K | 0.16% | 108 |
|
|
2021
Q4 | $2.64M | Sell |
30,161
-1,148
| -4% | -$95.3K | 0.17% | 110 |
|
|
2021
Q3 | $2.56M | Sell |
31,309
-215
| -0.7% | -$19.3K | 0.17% | 108 |
|
|
2021
Q2 | $2.88M | Buy |
31,524
+725
| +2% | +$64.6K | 0.19% | 101 |
|
|
2021
Q1 | $2.63M | Sell |
30,799
-809
| -3% | -$72.6K | 0.19% | 94 |
|
|
2020
Q4 | $2.98M | Sell |
31,608
-890
| -3% | -$77.8K | 0.23% | 89 |
|
|
2020
Q3 | $2.83M | Sell |
32,498
-135
| -0.4% | -$11.7K | 0.25% | 88 |
|
|
2020
Q2 | $2.85M | Sell |
32,633
-1,070
| -3% | -$92.4K | 0.26% | 88 |
|
|
2020
Q1 | $2.78M | Sell |
33,703
-1,948
| -5% | -$174K | 0.28% | 79 |
|
|
2019
Q4 | $3.38M | Sell |
35,651
-1,400
| -4% | -$126K | 0.17% | 95 |
|
|
2019
Q3 | $3.22M | Sell |
37,051
-3,084
| -8% | -$277K | 0.14% | 93 |
|
|
2019
Q2 | $3.67M | Sell |
40,135
-11,395
| -22% | -$964K | 0.15% | 93 |
|
|
2019
Q1 | $4.44M | Sell |
51,530
-83
| -0.2% | -$6.66K | 0.17% | 91 |
|
|
2018
Q4 | $3.97M | Sell |
51,613
-2,834
| -5% | -$221K | 0.17% | 92 |
|
|
2018
Q3 | $4.2M | Sell |
54,447
-246
| -0.4% | -$18.2K | 0.13% | 103 |
|
|
2018
Q2 | $3.7M | Sell |
54,693
-1,533
| -3% | -$106K | 0.12% | 110 |
|
|
2018
Q1 | $4.07M | Sell |
56,226
-5,470
| -9% | -$416K | 0.14% | 111 |
|
|
2017
Q4 | $4.64M | Buy |
61,696
+363
| +0.6% | +$27.4K | 0.15% | 107 |
|
|
2017
Q3 | $4.72M | Sell |
61,333
-963
| -2% | -$72.7K | 0.14% | 109 |
|
|
2017
Q2 | $4.66M | Sell |
62,296
-2,260
| -4% | -$160K | 0.13% | 107 |
|
|
2017
Q1 | $4.3M | Sell |
64,556
-4,115
| -6% | -$274K | 0.12% | 113 |
|
|
2016
Q4 | $4.48M | Sell |
68,671
-12,026
| -15% | -$780K | 0.12% | 109 |
|
|
2016
Q3 | $5.71M | Sell |
80,697
-23,542
| -23% | -$1.72M | 0.16% | 94 |
|
|
2016
Q2 | $7.71M | Buy |
104,239
+2,176
| +2% | +$150K | 0.23% | 84 |
|
|
2016
Q1 | $6.63M | Sell |
102,063
-2,985
| -3% | -$203K | 0.24% | 92 |
|
|
2015
Q4 | $8.1M | Sell |
105,048
-575
| -0.5% | -$45.7K | 0.28% | 81 |
|
|
2015
Q3 | $8.7M | Sell |
105,623
-918
| -0.9% | -$81.7K | 0.29% | 73 |
|
|
2015
Q2 | $9.39M | Buy |
106,541
+3,207
| +3% | +$294K | 0.24% | 75 |
|
|
2015
Q1 | $9.13M | Sell |
103,334
-56
| -0.1% | -$4.97K | 0.24% | 73 |
|
|
2014
Q4 | $8.58M | Buy |
103,390
+320
| +0.3% | +$26.5K | 0.22% | 75 |
|
|
2014
Q3 | $8.69M | Sell |
103,070
-212
| -0.2% | -$17.2K | 0.21% | 75 |
|
|
2014
Q2 | $8.38M | Sell |
103,282
-861
| -0.8% | -$67.7K | 0.21% | 74 |
|
|
2014
Q1 | $7.93M | Sell |
104,143
-9,801
| -9% | -$714K | 0.24% | 74 |
|
|
2013
Q4 | $8.21M | Sell |
113,944
-1,801
| -2% | -$125K | 0.26% | 75 |
|
|
2013
Q3 | $7.96M | Sell |
115,745
-6,215
| -5% | -$411K | 0.28% | 65 |
|
|
2013
Q2 | $7.73M | Buy |
+121,960
| New | +$7.93M | 0.29% | 60 |
|
Other funds holding NVS
Eagle Global Advisors's NVS Position: Q2 2026 in Review
Eagle Global Advisors held its Novartis (NVS) position steady in Q2 2026 at 1,395 shares worth $219K. The position accounts for 0.01% of the portfolio, ranked #262.
Eagle Global Advisors first reported a position in NVS in Q2 2013 and has held it in 42 quarters since. The position peaked at $9.39M in Q2 2015. 1,614 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Eagle Global Advisors held 1,395 shares of Novartis worth $219K as of Q2 2026.
- Eagle Global Advisors left its Novartis share count unchanged in Q2 2026.
- Novartis made up 0.01% of Eagle Global Advisors's portfolio in Q2 2026, its #262 holding.
- Eagle Global Advisors first reported a position in Novartis in Q2 2013 and has held it in 42 quarters since.
- Eagle Global Advisors's Novartis position peaked at $9.39M in Q2 2015.
- 1,614 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.